Hitachi and Axcelead have agreed to start joint development of solutions contributing on more efficient creation of next-generation biopharmaceuticals

2021-04-08
Hitachi, Ltd. (TSE:6501, "Hitachi") and Axcelead, Inc. (President: Tomoyuki Fujisawa, "Axcelead") today announced that they have agreed on a comprehensive collaborative partnership to develop solutions contributing on more efficient creation of next-generation biopharmaceuticals with digital technology and drug discovery platform. Hitachi has also made investment to Drug Discovery Gateway Fund ("DDG Fund") managed by Whiz Partners Inc. (President: Atsushi Matsumura, "Whiz"). Axcelead is the flagship portfolio company of DDG Fund.
To view the complete content, please log in.
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
JARN
 
 
 
 
Midez CAC